Lightlake Therapeutics' Binge Eating Disorder Treatment Phase II Trial Results Presented At APA 2013
Lightlake Therapeutics' Binge Eating Disorder Treatment Phase II Trial Results Presented At APA 2013 Annual Meeting
̶ Binge Eating Disorder Added to DSM-5 ̶̶
LONDON--(BUSINESS WIRE)-- Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake"), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder ("BED") were presented at the American Psychiatric Association ("APA") Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
BED has been added to the fifth edition of the APA's Diagnostic and Statistical Manual of Mental Disorders ("DSM-5"), which was launched at the APA Annual Meeting. DSM-5 is used by clinicians and researchers to diagnose and classify mental disorders in order to improve diagnoses, treatment, and research. This manual is the product of more than 10 years of effort by hundreds of international experts in all aspects of mental health. DSM-5 diagnostic criteria are concise and explicit, intended to facilitate an objective assessment of symptom presentations in a variety of clinical settings from inpatient to primary care. BED is defined in the DSM-5 chapter on Feeding and Eating Disorders as a diagnosis for individuals who experience persistent, recurrent episodes of overeating, marked by loss of control and significant clinical distress. The chapter also includes changes in the requirements for diagnosis of anorexia nervosa and bulimia nervosa, two potential additional indications for Lightlake's treatment.
"We are very pleased to see that Binge Eating Disorder has been added to the APA's DSM-5," commented Dr. Roger Crystal, Chief Executive Officer of Lightlake. "BED is one of the major causes of obesity and the most chronic and common of all eating disorders. Our intranasal naloxone is a truly differentiated treatment because it addresses harmful eating behavior, and inclusion in DSM-5 should help with reimbursement of therapies for BED."
About Lightlake Therapeutics Inc.
Lightlake Therapeutics Inc., a London-based biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative solutions to common addictions and related disorders. The Company holds patents covering the use of intranasal naloxone to treat Binge Eating Disorder ("BED") as well as patents covering addiction to drugs including cocaine, amphetamine, and MDMA. Lightlake is currently focused on advancing its treatment for BED, which has successfully completed Phase II clinical trials, and a Phase II trial is planned for the indication of Bulimia Nervosa. Lightlake is also applying its technology to develop a treatment for managing the complications of opioid drug addiction in collaboration with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.
Forward Looking Statement
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward- looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Lightlake Therapeutics Inc.
Dr. Roger Crystal, +44(0)203 617 8739
Chief Executive Officer
Porter, LeVay & Rose, Inc.
Michael J. Porter, 212-564-4700
KEYWORDS: United Kingdom United States Europe North America California
The article Lightlake Therapeutics' Binge Eating Disorder Treatment Phase II Trial Results Presented At APA 2013 Annual Meeting originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.